中兵紅箭(000519.SZ)一季度淨利預增341.77%-402.01%
格隆匯4月15日丨中兵紅箭(000519.SZ)披露2021年第一季度業績預吿,公司預計2021年1-3月實現歸屬於上市公司股東的淨利潤0.88億元-1.00億元,同比增長341.77%-402.01%。
2021年一季度,隨着國內疫情得到有效控制,市場供需關係同比發生重大變化,同時,隨着國內經濟的發展,行業供需結構產生局部調整,公司管理層認真研判形勢發展,深挖主業發展潛力,緊跟市場需求,使得超硬材料等主要產品銷售量大幅度增長,經濟效益持續改善。同時,公司實施的提質增效措施效果初步顯現,困難企業虧損總額同比下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.